Abstract:Although a clear mechanism underlying the pathophysiology of schizophrenia (SZ) remains elusive, oxidative stress, inflammatory syndrome and immune activation have become an attractive hypothesis for explaining the pathophysiology of SZ. Data from prior studies on the role of matrix metalloproteinase 9 (MMP-9) and brain-derived neurotrophic factor (BDNF) single nucleotide polymorphisms (SNPs) in SZ are contradictory. We aimed to investigate whether oxidative stress, inflammatory and immune activation markers as well as MMP-9 levels may be implicated in SZ pathogenesis. The association of MMP-9 and BDNF SNPs with the clinical expression of SZ was examined.Ninety-four subjects were recruited, including 44 SZ patients and 50 healthy controls. Serum levels of thiobarbituric acid reactive substances (TBARS), protein carbonyl content (PCC), nitrite, C-reactive protein (CRP), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), Beta-2 microglobulin (Β2M), complement component 3 (C3), C4 and MMP-9 were measured. The MMP-9 − 1562C > T and BDNF196G > A SNPs were genotyped using polymerase chain reaction-restriction fragment length polymorphism assay. Psychopathology was assessed using the positive and negative syndrome scale (PANSS).SZ patients showed significantly higher TBARS, PCC, nitrite, CRP, IL-6, TNF-α, Β2M, C3 and MMP-9 levels than controls. In distinguishing SZ patients from healthy controls, CRP and MMP-9 yielded similar discriminatory performance, and both perform better than IL-6, Β2M, C3, nitrite, TBARS, PCC, TNF-α and C4. The MMP-9 − 1562C > T SNP genotypes distribution didn't differ significantly between controls and SZ patients. As compared to controls, SZ patients harbor a significantly higher frequency of the BDNF196GG genotype and a lower frequency of the BDNF196GA/AA genotype. Patients carrying the MMP-9 − 1562CC or BDNF196GG genotype revealed a significantly higher PANSS than those carrying MMP-9 − 1562CT/TT or BDNF196GA/AA genotype. Male gender and the MMP-9 − 1562CC genotype were identified as independent predictive factors for higher PANSS.Redox dysregulation and alterations in the immuno-inflammatory pathways are major culprits in the pathogenesis of SZ. MMP-9 and BDNF SNPs are associated with the clinical phenotype of SZ and, thus, may be a useful marker predicting the phenotypic expression and prognosis of SZ patients.

Elevated activity of plasma superoxide dismutase in never-treated first-episode schizophrenia patients: Associated with depressive symptoms

Imbalanced Free Radicals and Antioxidant Defense Systems in Schizophrenia: A Comparative Study

Superoxide Dismutase and Cytokines in Chronic Patients with Schizophrenia: Association with Psychopathology and Response to Antipsychotics

Elevated activity of superoxide dismutase in male late-life schizophrenia and its correlation with clinical symptoms and cognitive deficits

Elevated Blood Superoxide Dismutase in Neuroleptic-Free Schizophrenia: Association with Positive Symptoms

The C(−1562)T Polymorphism of Matrix Metalloproteinase-9 Gene is Associated with Schizophrenia in China

Sex-specific association between peripheral superoxide dismutase, BDNF and cognitive impairment in drug-naive first episode patients with schizophrenia

Plasma Superoxide Dismutase Activity in Relation to Disability in Activities of Daily Living and Objective Physical Functioning among Chinese Older Adults

Clinical Symptoms and Cognitive Impairment Associated with Male Schizophrenia Relate to Plasma Manganese Superoxide Dismutase Activity: a Case-Control Study.

Cognition Impairment in Schizophrenia Patients with Tardive Dyskinesia: Association with Plasma Superoxide Dismutase Activity.

Blood Superoxide Dismutase Level in Schizophrenic Patients with Tardive Dyskinesia: Association with Dyskinetic Movements

Differential Impacts of Endogenous Antioxidants on Clinical Symptoms and Cognitive Function in Acute and Chronic Schizophrenia Patients

The Interplay Between BDNF and Oxidative Stress in Chronic Schizophrenia

The association of SOD and HsCRP with the efficacy of sulforaphane in schizophrenia patients with residual negative symptoms

Association between MnSOD Activity and Cognitive Impairment in Unmedicated First-Episode Schizophrenia: Regulated by MnSOD Ala-9Val Gene Polymorphism

Sex Difference in the Interrelationship Between TNF-α and Oxidative Stress Status in First-Episode Drug-Naïve Schizophrenia.

Manganese superoxide dismutase gene expression and cognitive functions in recurrent depressive disorder.

Cognitive Impairment and Psychopathology Are Related to Plasma Oxidative Stress in Long Term Hospitalized Patients With Chronic Schizophrenia

Plasma oxidative stress marker levels related to functional brain abnormalities in first-episode drug-naive major depressive disorder

Catalase and interleukin-6 serum elevation in a prediction of treatment-resistance in male schizophrenia patients

A Meta-Analysis of Oxidative Stress Markers in Schizophrenia